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Abstract 
Real-time screening of cellular response on the drugs could provide valuable insights for the early 
detection of therapeutic efficiency and the evaluation of disease progression. Cancer cells have the 
ability to vary widely in response to stress in a manner to adjust the signaling pathway to promote 
the survival or having a resistance to stimulation. Cell-based label-free technologies using 
electronic impedance sensor have strategies for constructing the signature profiles of each cells. 
To achieve exquisite sensitivity to substantially change of live-cell response have an important role 
that predict the potential of therapeutic effects. In this study, we use an impedance-based real-time 
cell analysis system to investigate dynamic phenotypes of cells described as a cellular index value. 
We show that gastric cancer cells generated characteristic kinetic patterns that corresponded to 
the treatment order of therapeutics. The kinetic feature of the cells offers insightful information 
that cannot be acquired from a conventional single end-point assay. Furthermore, we employ a 
‘sequential treatment strategy’ to increase cytotoxic effects with minimizing the use of 
chemotherapeutics. Specifically, treatment of paclitaxel (PTX) after down-regulating Akt gene 
expression using RNAi reduces the cell proliferation and increases apoptosis. We propose that the 
sequential treatment may exhibit more effective approach rather than traditional combination 
therapy. Moreover, the dynamic monitoring of cell-drug interaction enables us to obtain a better 
understanding of the temporal effects in vitro. 
Key words: Akt; gastric cancer; paclitaxel (PTX); real-time cell analysis (RTCA); sequential treatment, small 
interfering RNA (siRNA). 
Introduction 
Paclitaxel (PTX), a microtubule-targeted drug, is 
one of the most widely used chemotherapeutic agents 
against ovarian, breast, brain and prostate cancers [1]. 
Recently, PTX has been tested in advanced gastric 
cancers and is now considered a key drug for clinical 
study [2, 3]. PTX has been proven to block the growth 
and proliferation of cancer cells by preventing the 
disassembly and stabilizing of microtubules against 
depolymerization [4, 5]. PTX induces cell death by 
apoptosis and regulates the expression of tumor 
suppressor genes and cytokines [6, 7]. However, PTX 
chemotherapy often results in serious 
chemo-resistance to PTX and its DNA-damaging 
effects [8]. Mechanistically, PTX is associated with 
elevated level of Akt that closely related to multiple 
cellular processes such as cell growth, proliferation, 
and cell migration [9, 10]. To enhance the efficacy of 
cancer chemotherapy, various therapeutic strategies 
have been reported such as using combinations of 
signaling inhibitors, incorporation of adjuvant 
chemotherapy, down-regulation of apoptotic gene 
expression and thermo-chemotherapy [11, 12]. As 
with many anticancer drugs, the chemo-sensitivity of 
cancer cells must be increased in an effort to increase 
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the effectiveness of PTX, otherwise, the usage of PTX 
must be minimized to reduce side effects; this may 
result in sub-therapeutic levels of drug. Targeting 
gene signaling pathways to improve therapeutic 
response is considered a suitable approach to these 
issues [13-15]. The chemo-sensitivity of cancer cells to 
PTX depends on the activation of a signal 
transduction pathway involved in cell proliferation 
[16]. Previous researches have suggested that the 
serine/threonine kinase Akt plays a prominent role as 
a key mediator of cellular survival pathways and 
contributes to chemotherapeutic resistance [17, 18]. 
Akt expression inhibits apoptosis through 
anti-apoptotic Bcl-2 family members and controls 
multiple intracellular targets. In addition, Akt 
regulates glycolytic activity that coordinately affects 
the cellular response to chemotherapeutic agents 
against selected critical targets of signaling pathways 
[18-21].  
On the other hand, dysregulated cell metabolism 
has been linked to clinical relevant area for cancer 
therapy [22]. Cancer cells can be reprogrammed in 
bioenergetics and biosynthetic metabolism that 
results from multiple genetic changes and cellular 
abnormalities [23-25]. To predict the response of the 
cancer cells to therapeutic agents is convoluted 
argument because molecular mechanism of cancer 
cells is complicated and diverges significantly from 
those of normal cells. Therefore, in terms of the 
complexity of cancer progression mechanisms and 
heterogeneity, a significant problem for cancer 
therapy is how to overcome the anticancer drug 
resistance and how to detect and observe a change in 
the cellular response. Most of the usual approaches to 
monitor cellular responses after drug treatment only 
show a dose-dependent cytotoxic effects and the 
conclusion regarding the mechanism of action for the 
drug that has multiple and kinetically distinct effect 
based upon the time point. Our aim was to find 
effective strategy for cancer therapy by controlling 
variable condition such as the time point, dose 
concentration and order of sequential administration 
to elevate combination effects of the same drugs in 
cancer cells [26]. Moreover, it requires multiple 
variables to determine the changed molecular 
signaling pathways involved in tumor progression 
followed by balloon effects took place in response to 
an external stimulus. Therefore, we presented 
importance in combination and sequential treatment 
to elevate combination effects in cancer cells. For the 
evaluation of biological response to drug interaction 
with cells in entire course, in recent, the real-time cell 
analysis (RTCA) was used to quantitatively monitor 
the changes in cells during the course of our 
experiments [27]. RTCA measures the electrical 
impedance-based signals of adherent cells taken from 
an electronic sensor plate reflect changes in cellular 
parameters. The cellular index digitally represents cell 
proliferation, changes in adhesion and/or attachment 
of cells to microelectrode and cell morphology. RTCA 
is a novel tool that allows for label-free detection and 
long-term assay of live cells. Moreover, RTCA has a 
wide range of applications such as monitoring of 
cell-mediated cytotoxicity, screening of RNAi (RNA 
interference) effects and invasion/migration of cells 
[28]. These results provide evidence for the 
systemized therapeutic strategy should be developed 
to enhance the effectiveness of chemo-treatment 
without unwanted side effects and the real-time 
monitoring of cellular responses will be helpful to 
establish a more effective treatment strategy 
In this study, the in-situ profiles for a 
proliferation of gastric cancer cells after RNAi and 
chemo-treatment in a sequential manner were 
monitored by RTCA. Here, small interfering RNA 
(siAkt) was used to specifically silence Akt oncogene 
expression and PTX was selected to disturb the 
stability of microtubules. The inhibition of Akt would 
extensively increase the PTX-induced cytotoxicity in 
gastric cancer cell lines. To predict the efficacy from 
the sequential treatment using siAkt and PTX, 
moreover, the treatment intervals and the order of 
therapeutic agents were controlled.  
Materials and methods 
Cell culture 
Human gastric cancer cell lines (MKN28 and 
MKN45 cells) were obtained from the American Type 
Culture Collection (Manassas, VA, USA) and cultured 
at 37°C in 5% CO2 humidified atmosphere in RPMI 
1640 medium supplemented with 10% fetal bovine 
serum. Cellular morphology was observed using an 
Olympus® microscope and microscopic images were 
captured with an Olympus® digital camera. 
PTX treatment 
PTX was provided by Sigma-Aldrich (St. Louis, 
MO, USA, Cat. #T7191) and dissolved in dimethyl 
sulfoxide (DMSO) as a 10 mM stock solution. MKN28 
and MKN5 cells were plate at 1 × 104 cells per well in 
96-well plate. After incubating for 24 h at 37°C, cells 
were incubated with PTX.  
siRNA transfection  
MKN28 and MKN45 cells were plated at 2 × 105 
cells per well in 6-well dishes and 1 × 104 cells per well 
in E-plate 16 to 70-80% confluence and transfected 
using Lipofectamine 2000 transfection reagent 
according to the manufacturer’s protocol (Life 
Technologies, Inc., Gaithersburg, MD, USA). MKN28 
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and MKN45 cells were transfected with the siRNA for 
knockdown of Akt (ON-TARGETplus Human Akt1 
(207) siRNA-SMARTpool, Cat. #L-003000-00-0010, 
Dharmacon, Lafayette, CO, USA), and scrambled 
siRNA (ON-TARGETplus Non-targeting pool, Cat. 
#D-001810-10, Dharmacon) at 100 nM final 
concentration using Lipofectamine 2000 and 
Opti-MEM medium following the protocols 
recommended by the manufacturer (Thermo 
Scientific, Waltham, MA, USA). 
Real-time Cell Analysis (RTCA) 
Real-time cellular proliferations for MKN28 and 
MKN45 cells were analyzed using the xCELLigenceTM 
DP system (Roche Diagnostics GmbH, Berlin, 
Germany). For the monitoring of cell index, MKN28 
and MKN45 cells were seeded in the E-plate 16 
(ACEA Biosciences, San Diego, CA, USA) at a density 
of 1 × 104 cells per well and incubated for 24 h. After 
24 h, the cells were tested using five experimental 
conditions: DMSO-treated cells as a control (NT, ●), 
siAkt transfection (siAkt only, ○), simultaneous 
treatment of siAkt and PTX (siAkt & PTX, ▼), siAkt 
transfection after PTX treatment in sequential manner 
(PTX→siAkt, △) and PTX treatment after siAkt 
transfection in sequential manner (siAkt→PTX, ■). 
According to these treatment conditions, the cells 
were incubated at 37°C in a 5% CO2 humidified 
atmosphere and automatically monitored real-time at 
every 1 h by the xCELLigence system and expressed 
as a CI (cell index) value. The CI calculation is based 
on the following formula: CI = (Zi – Z0)/15ς (Zi: the 
impedance at an individual point of time during 
the experiment, Z0: the impedance at the start of the 
experiment) [29]. Data for cell adherence were 
normalized at 24 h after cell seeding. Normalized CI is 
calculated by dividing CI at the normalized time into 
the original CI. All experiments were performed in 
triplicate and the average and standard deviation 
were reported.  
Quantitative real-time PCR 
Total RNA was extracted from harvested gastric 
cancer cells using the Ambion mirVanaTM miRNA 
Isolation Kit (Cat # AM1560, Ambion, Austin, TX, 
USA). The quality of the isolated RNA was assessed 
using a NanoDrop Lite Spectrophotometer (Thermo 
Scientific). All samples had a 260/280 ratio of ~2.0. 
Total RNA was converted to cDNA using the high 
capacity RNA-to-cDNA kit (Cat # 4387406, Applied 
Biosystems, Carlsbad, CA, USA) according to the 
manufacturer’s recommendation. cDNA synthesis 
using 1 μg of RNA per 20 μL reaction was performed 
using the Roche LightCycler® system (Roche 
Diagnostics). Quantitative real-time PCR was 
performed in triplicate using HiFast SYBR Lo-Rox 
reagents (Cat. #Q100240, GenePool, Edinburgh, UK). 
Thermo-cycling conditions were as follows: initial 
denaturation at 95°C for 10 min followed by 45 cycles 
at 95°C for 10 sec and 60°C for 30 sec (annealing and 
extension). Sequences of specific primer sets used in 
this study are listed in Table 1. Primer sequences were 
designed using the Primer3 software 
(http://frodo.wi.mit.edu/primer3/). The 2-ΔΔCt 
method was used to calculate fold differences in gene 
expression, using the beta-Actin gene (β-actin) as 
housekeeping reference for data normalization. PCR 
products were subjected to melting curve analysis to 
rule out the synthesis of non-specific products.  
 
Table 1. mRNA primer sequences used for Quantitative 
real-time PCR analysis. 
Target Gene Primer Sequence 
AKT Forward: TCT ATG GCG CTG AGA TTG TG 
Reverse: CTT AAT GTG CCC GTC CTT GT 
Bcl-xL Forward: GCG TGG AAA GCG TAG ACA AG 
Reverse: TGC TGC ATT GTT CCC ATA GA 
Bcl-2 Forward: GTT GCT TTA CGT GGC CTG TT 
Reverse: CAG GTT TCC TGC TTT CTT GG 
Bad Forward: GCC GAG TGA GCA GGA AGA 
Reverse: ACT GGC GTC CCA CAG GAG 
Caspase3 Forward: AAG ATC ACA GCA AAA GGA GCA 
Reverse: CAA CGA TCC CCT CTG AAA AA 
β-actin Forward: CTC TTC CAG CCT TCC TTC CT 
Reverse: TGT TGG CGT ACA GGT CTT TG 
 
 
Statistical analysis 
In vitro results are expressed as mean ± standard 
deviation. Student’s t-test was performed to 
determine statistically significant differences between 
groups, and a p values (<0.01 or 0.05) were considered 
statistically significant. Error bars denote the standard 
error (n = 3). 
Results 
Chemo-sensitivity of PTX to gastric cancer 
cell lines 
To investigate the chemo-cytotoxic effect of PTX 
on gastric cancer cell lines, cellular proliferation was 
monitored by a real-time and label-free method. The 
microelectrodes measure the electrical impedance that 
reflects interaction between cell population and the 
sensor surface in each well and it provides 
quantitative kinetic trace about the status of the cells 
[30]. MKN28 and MKN45 cells were respectively 
seeded into microelectrodes-deposited wells and 
treated with PTX at various concentrations from 100 to 
104 nM. At higher PTX concentrations, round cellular 
morphology was observed in both PTX-treated 
MKN28 and MKN45 cells compared to the flat control 
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cells (Figure 1A). The cytotoxic effects of PTX on both 
MKN28 and MKN45 cells were subsequently 
monitored for 24 h after the treatment of PTX. 
Compared to DMSO control without PTX treatment, 
the normalized cell indexes for MKN28 and MKN45 
cells presented remarkable differences as an increase 
of PTX concentration (Figure 1B). The 50% inhibitory 
concentration (IC50) values of PTX for MKN28 (23 nM) 
or MKN45 cells (60 nM) were calculated after 24 h 
exposure to PTX (Figure 1C).  
Specific modulation of Akt expression in 
gastric cancer cell lines 
In order to determine the optimal transfection 
condition of siRNA, gel retardation assay was 
performed to evaluate the degree of binding between 
Lipofectamine and siAkt at varying weight ratios. A 
series of Lipofectamine/siAkt complexes in ratios 
(w/w) of 0.25:1, 0.5:1, 1:1, 2:1, and 4:1 were examined 
and 1:1 ratio was selected for the target gene 
down-regulation assay. Thus, MKN28 and MKN45 
cells were respectively transfected with 50, 100, and 
200 nM of siAkt and 50 nM scrambled siRNA (siScr) 
as a control to evaluate the transfection efficiency of 
siAkt. Clear down-regulations of Akt mRNA for both 
cell lines were revealed by quantitative real-time PCR 
(Figure 2A and 2B). The inhibitory effect in gene 
regulation was minimal at 50 nM of siAkt in both 
MKN28 and MKN45 cells. In contrast, over 100 nM of 
siAkt exhibited effective inhibitory effect in Akt 
mRNA expression for both MKN28 and MKN45 cells 
rather than the other transfection conditions. 
Subsequently, normalized cell indexes for cellular 
proliferations of MKN28 and MKN45 cells were 
monitored (Figure 2C and 2D). In both cell lines, the 
reduced proliferations were remarkably observed at 
100 and 200 nM of siAkt (p<0.01).  
Sequential treatment of siAkt and PTX for 
MKN28 cells 
To investigate the cytotoxic efficacy of sequential 
treatment of siAkt and PTX, the proliferation for two 
gastric cancer cells were monitored under five 
different treatment conditions (Figure 3A); 
non-treatment control (NT→NT, CTRL, ●), siAkt 
transfection (siAkt→NT, siAkt only, ○), simultaneous 
treatment of siAkt and PTX (siAkt & PTX→NT, ▼), 
siAkt transfection after PTX treatment in sequential 
steps (PTX→siAkt, △), and PTX treatment after siAkt 
transfection in sequential steps (siAkt→PTX, ■). Here, 
concentrations of siAkt and PTX were 100 nM and 70 
nM to evaluate the cytotoxic efficacy from the 
sequential treatment, respectively. In order to 
determine the proper interval time point of the 
sequential treatment, time intervals between the first 
and second treatment were 12 h, 24 h, and 48 h. 
 
Figure 1. Chemo-sensitivity of PTX on gastric cancer cell lines. (A) Cellular microscopic images for MKN28 and MKN45 cells at 24 h after addition of PTX. Scale bars 
mean 50 μm. (B) Proliferation profiles for MKN28 (left) and MKN45 (right) cells obtained by the RTCA after 24 h from PTX treatments (0 - 104 nM, 1:10 serial dilutions). All 
graphs represent three independent experiments and with standard deviations (n = 3). (C) Cell viabilities for MKN28 and MKN45 cells calculated from (B) at 24 h from PTX 
treatment. 
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Morphological change and rounding up in the cells 
due to the cellular damage from sequential treatment 
were observed (Figure 3B). At both 24 h and 48 h of 
time intervals, siAkt→PTX condition (■) exhibited the 
greatest cytotoxic efficacy compared to other 
conditions (Figure. 3C). At 12 h of time interval, 
interestingly, both siAkt→NT (○) and siAkt & 
PTX→NT (▼) conditions presented the rebound of 
cell proliferation from 12 h after the treatment of 
therapeutics. Only siAkt→PTX (■) condition 
appeared continuous cytotoxic effect during a 
monitoring period. Furthermore, there was no 
effective reduction of cell proliferation under only 
siAkt transfection condition (siAkt→NT, ○). As 
shown in Figure. 3D, the case for 24 h of time interval 
exhibited the greatest cytotoxic effect with 63% rather 
than any other treatment groups. 
Sequential treatment of siAkt and PTX for 
MKN45 cells 
As indicated in Figure 4A, the cytotoxic efficacies 
for MKN45 cells were evaluated by five sequential 
treatment conditions. Similar to the case of MKN28 
cells, cellular damages were observed by a 
microscopy after the sequential treatments (Figure 
4B). However, the cytotoxic capacity from siAkt→PTX 
(■) condition using 100 nM of siAkt was not 
significant and reduced normalized cell index was 
53% (Figure 4C and 4D). When the transfection 
concentration of siAkt was increased with 200 nM, the 
enhancement of cytotoxic effect against MKN45 cells 
was confirmed after the sequential treatment of siAkt 
and PTX (Figure 4C). Normalized cell index for 
siAkt→PTX (■) condition was gradually decreased 
and Δ normalized cell index was lowest with 87% in 
MKN45 cells compared to other treatment conditions.  
Apoptotic effects of sequential treatment of 
siAkt and PTX  
To analyze apoptotic effects on MKN28 and 
MKN45 cells by the sequential treatment of siAkt and 
PTX, the expressions of apoptosis-related genes were 
investigated using quantitative real-time PCR. As 
shown Figure 5, the level of Akt expression for 
siAkt→PTX (■) condition was significantly lower than 
(NT→NT, CTRL, ●) in both MKN28 and MKN45 cells. 
On the contrary, we found that Akt gene expression 
was elevated when siAkt was used after PTX 
treatment. Furthermore, we focused on the expression 
levels of pro-apoptotic Caspase-3 and Bad proteins 
and anti-apoptotic Bcl-xL and Bcl-2 proteins. The 
sequential treatment of siAkt and PTX induces 
molecular events that increase pro-apoptotic proteins 
and decrease anti-apoptotic proteins, relatively. The 
mRNA expression levels of Bcl-xL and Bcl-2 were 
decreased in both MKN28 and MKN45 cells, whereas 
the mRNA expression levels of Caspase-3 tended to 
be inconsistent.  
 
Figure 2. Effects of siAkt on gastric cancer cell lines. Relative Akt mRNA expression levels as a function of siScr and siAkt in a dose-dependent manner for (A) MKN28 
and (B) MKN45 cells. Proliferation profiles monitored by RTCA for (C) MKN28 and (D) MKN45 cells treated with 50 nM of scrambled siRNA (siScr) and 50, 100, and 200 nM 
of siAkt, respectively. The normalized cell index was calculated every 2 h. All graphs represent three independent experiments and with standard deviations (n = 3). *p<0.01. 
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Figure 3. Sequential treatment of siAkt and PTX against MKN28 cells. (A) The index for sequential treatment of siAkt and PTX; DMSO treatment as a control (NT, 
●), siAkt transfection (siAkt only, ○), simultaneous treatment of siAkt and PTX (siAkt & PTX, ▼), siAkt transfection after PTX treatment in sequential manner (PTX→siAkt, △), 
and PTX treatment after siAkt transfection in sequential manner (siAkt→PTX, ■). (B) Cellular microscopic images for MKN28 cells after the sequential treatment of siAkt and 
PTX at the indicated treatment time; △t = 12, 24, and 48 h. (C) Normalized proliferation profiles of MKN28 cells after the sequential treatment of siAkt and PTX. (D) 
ΔNormalized cell index calculated from (C). Non-treatment condition was used as a control. *p<0.01. 
 
 
Figure 4. Sequential treatment of siAkt and PTX against MKN45 cells. (A) The index for sequential treatment of siAkt and PTX; DMSO treatment as a control (NT, 
●), siAkt transfection (siAkt only, ○), simultaneous treatment of siAkt and PTX (siAkt & PTX, ▼), siAkt transfection after PTX treatment in sequential manner (PTX→siAkt, △), 
and PTX treatment after siAkt transfection in sequential manner (siAkt→PTX, ■). (B) Cellular microscopic images for MKN45 cells after the sequential treatment of siAkt and 
PTX at 24 h of treatment time; 100 (left column) and 200 nM (right column) of siAkt. (C) Normalized proliferation profiles of MKN45 cells after the sequential treatment of siAkt 
and PTX; 100 (left) and 200 nM (right) of siAkt. (D) ΔNormalized cell index calculated from (C). Non-treatment condition was used as a control. *p<0.01. 
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Figure 5. Apoptosis-related gene expressions after the sequential 
treatment of siAkt and PTX on gastric cancer cell lines. (A) The index for 
sequential treatment of siAkt and PTX; DMSO treatment as a control (NT, ●), siAkt 
transfection (siAkt only, ○), simultaneous treatment of siAkt and PTX (siAkt & PTX, 
▼), siAkt transfection after PTX treatment in sequential manner (PTX→siAkt, △), 
and PTX treatment after siAkt transfection in sequential manner (siAkt→PTX, ■). 
Total RNA was extracted from the cells at 24 h of treatment time. The RNA samples 
were subjected to qRT-PCR to analyze apoptosis-associated genes (Akt, Bcl-xL, Bcl-2, 
Bad, and Caspase-3) of interest in (B) MKN28 and (C) MKN45 cells. *p<0.01. 
 
Discussion 
PTX, the anti-mitotic antitumor drug, has been 
extensively used for the treatment of a variety of 
human gastric cancers [31]. PTX suppresses 
microtubule dynamics and function via control of cell 
signaling, mitotic activity and proliferative capacity 
[4]. Microtubules are the major cytoskeletal 
components and are considered as an essential target 
for anticancer therapy [5]. Although 
microtubule-targeted PTX has shown clinical success, 
drug resistance and cellular toxicity frequently lead to 
cancer treatment failure [7, 32]. In particular, cancer 
cells develop complex mechanisms to evade the 
chemotherapeutic effect of the drug. These molecular 
mechanisms induce drug resistance as well as lower 
sensitivity to drugs [33]. To decrease 
chemotherapeutic resistance and increase the 
effectiveness of chemotherapy for refractory cancers, 
a strategy using combination therapy targeting 
apoptosis-related pathways still represents one of the 
best solutions.  
 On thither hand, Akt plays a major role in a 
fundamental signaling pathway that includes cell 
proliferation, growth and survival. Akt has 
previously been demonstrated as a key protein 
associated with chemo-sensitivity for a variety of 
cancers [17]. In addition, Akt-related signaling 
pathway can control glucose metabolism and cellular 
energy mechanism and acts as a positive regulator of 
numerous downstream targets to shift the apoptotic 
threshold in cancer cells [34-36]. Moreover, Akt 
signaling inactivates pro-apoptotic factors, including 
the Bcl-2 family, and caspase-9, and also up-regulates 
anti-apoptotic genes by activating transcription 
factors [34]. Therefore, Akt is a reasonable target for 
the development of chemotherapeutics against a 
central node in the cell survival signaling process.  
 As discussed, our study tested a regimen 
combining standard chemotherapy and RNAi to 
block signaling pathways that may influence 
chemo-sensitivity in gastric cancer. In particular, the 
combination treatment of chemotherapeutics and 
RNAi has been conducted in sequential manner. 
RNAi-mediated knockdown of specific gene has been 
confirmed as an effective method to inhibit target 
protein expression [37]. Short interfering RNA 
(siRNA) has potential as a more intelligent 
therapeutic approach by specifically and efficiently 
recognizing a single point in targeted gene expression 
[38]. Thus, RNAi has been considered a potent 
chemo-enhancer to existing chemotherapy agents 
[39]. In this study, we investigated whether Akt 
down-regulation would result in increased 
chemotherapeutic efficacy of PTX in human gastric 
cancer cell lines. By comparing dosing interval and 
exposure order of siAkt and PTX, we found that the 
sequential treatment was more effective when 
combining two therapeutic drugs that act respectively 
via different mechanisms. Hence, we focused on 
sequential treatment using Akt-regulating siRNA 
using a conventional transfection reagent and the 
anticancer drug PTX on two gastric cancer cell lines. 
We have conducted a series of in vitro studies under 
various treatment conditions such as non-treatment as 
a control, siAkt transfection, siAkt and PTX 
simultaneously treatment, siAkt transfection after 
PTX-treatment in a sequential manner and 
PTX-treatment after siAkt transfection in a sequential 
manner to compare the cytotoxic effects. We used two 
gastric cancer cell lines (MKN28 and MKN45) to 
investigate changes in gene expressions and 
cytotoxicity from the sequential treatment of siAkt 
and PTX.  
On the other hand, in vitro assessment of the cell 
viability and proliferation pattern of cancer cells is 
essential for the understanding of cytotoxic effects 
and a screening of meaningful therapeutics. However, 
the conventional tetrazolium-based viability assays 
reveal the endpoint results that can ignore the 
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relevant in-situ biochemical event in living cells. To 
obtain the data for cellular viabilities at numerous 
time points, moreover, abundant cell samples are 
needed. To address these limitations, in recent, the 
impedance-based real-time cell analyzing system has 
developed and extended to a wide range of in vitro 
applications for label-free detection of cell processes 
directly [40]. Here, the impedance value demonstrates 
the collected information of cellular events that 
include the relative density, changes in cell 
morphology, attachment and spreading of cell on the 
electrodes that occur over several days. Therefore, the 
extended validation by a dynamic monitoring of 
cellular plasticity and the progression of cancer cells is 
significant to test the overall efficiency of therapeutics. 
A major finding from our experiments was that 
when cells were pretreated with 100 nM of siAkt for 
24 h before incubation with a low dose of PTX, at 
lower concentration than approximating the IC50 of 
PTX in both two cell lines, the cytotoxic effects were 
enhanced. Our data present that PTX may drive the 
elevation of Akt level, thereby promoting survival 
and resistance to RNAi treatment. In contrast, 
inhibition of Akt expression via siRNA led to 
increased PTX-induced cytotoxic effect against both 
MKN28 and MKN45 cells (Figure. 5F). Therefore, our 
results also raise questions about the importance of 
the sequence-dependent regimen in the clinical 
formulation of the multi-target therapy. In particular, 
there are no critical differences in cell indexes and 
mRNA levels of Akt after the transfection of siAkt 
with 100 and 200 nM. When PTX was treated in 
siAkt-transfected gastric cancer cells, however, 
distinct changes of cell index were observed at each 
siAkt transfection condition. Various previous studies 
have reported that the regulation of Akt-related 
signaling might change a cellular fate and the 
sensitivity and/or resistance in treated therapeutics 
[41, 42]. It means that the dose-dependent control of 
Akt signaling may affect PTX-sensitivity in gastric 
cancer cells. To better understand the mechanism of 
apoptosis by sequential treatment, we compared the 
expression levels of pro-/anti- apoptotic-related 
genes that are associated with multiple intracellular 
signaling pathways. The present results indicated that 
Akt has been shown to regulate cell survival and 
suppress apoptosis [21]. Therefore, we investigated 
Bcl-2 family proteins involved in the anti-apoptotic 
effects and Akt and caspase-3 expression, which 
interact to regulate programmed cell death [43, 44]. 
Results showed that sequential treatment of 
PTX-treatment after siAkt-transfection slightly 
increased the expression levels of caspase-3 and 
dominantly decreased Bcl-xL and Bcl-2 gene levels. 
The results presented that the level of anti-apoptotic 
signal was significantly correlated with cancer cell 
apoptosis, support our concept of sequential therapy.  
In conclusion, our findings demonstrated that 
the anticipative suppression of Akt expression and 
sequential PTX-treatment had increased the cytotoxic 
effect toward gastric cancer cell lines. In particular, 
the real-time profiling of the cellular proliferating 
state as a reaction to therapeutic compounds in 
sequential steps enable to clearly elucidate the 
optimal treatment step that influenced on multiple 
cells. The treatment of siAkt and PTX in a sequential 
manner has induced the apoptosis of gastric cancer 
cells compared to single treatment of siAkt or PTX. 
These findings provide a strong rationale for 
establishment of a promising strategy for clinical trials 
with anticipative suppression of Akt expression and 
sequential PTX-treatment on gastric cancer. In 
addition, our observations in gastric cancer cells are 
being expanded to undertake similar studies in a 
variety of human cancer cell lines. Further 
characterization of the sequential treatment for 
therapeutic efficiency of RNAi and 
chemotherapeutics will be helpful for clinical utility. 
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